Lancet Oncol:满足 vs 不满足USPSTF筛查标准的肺癌患者,5年生存率相似

2019-06-30 Lisa 肿瘤资讯

美国预防服务工作小组(USPSTF)推荐对年龄55-80岁,吸烟史达到30包年及以上或戒烟时间少于15年的人群进行肺癌筛查。然而,临床上很多肺癌患者并不符合这一筛查标准,如年轻肺癌患者和长期戒烟者。近期Lancet Oncology杂志发布的一项研究对满足 vs 不满足USPSTF筛查标准的肺癌患者进行生存对比。

美国预防服务工作小组(USPSTF)推荐对年龄55-80岁,吸烟史达到30包年及以上或戒烟时间少于15年的人群进行肺癌筛查。然而,临床上很多肺癌患者并不符合这一筛查标准,如年轻肺癌患者和长期戒烟者。近期Lancet Oncology杂志发布的一项研究对满足 vs 不满足USPSTF筛查标准的肺癌患者进行生存对比。

背景

国家肺癌筛查试验(NLST)的结果显示,对高危人群采用低剂量螺旋CT筛查,可以降低20%的肺癌病死率。基于此,美国预防服务工作小组(USPSTF)推荐对年龄55~80岁,吸烟史达到30包年及以上或戒烟时间少于15年的人群进行肺癌筛查。一项对比性模型研究显示,基于USPSTF标准,如果对美国符合筛查标准的人群进行广泛的低剂量CT筛查,那么每年可以避免约18000例肺癌死亡。来自SEER数据库和其他两个独立队列的研究显示,美国每年的新发肺癌患者中,仅1/3满足USPSTF高危人群标准,提示很多潜在高危人群并不适合进行低剂量CT筛查。对于不符合USPSTF高危人群标准的,有3部分人群可能是肺癌的高风险人群:在诊断肺癌前15~30年戒烟(定义为长期戒烟者);诊断为肺癌时年龄为50~54岁(定义为年轻人群组);吸烟史20~30包年人群,这几类人群罹患肺癌的风险相对较高。既往的研究显示,接近2/3的新发肺癌患者并不符合USPSTF标准,接近1/5的患者为长期戒烟者或年轻肺癌患者。不同于USPSTF标准,IASLC、AATS、ACCP、NCCN推荐根据NLST吸烟史标准或年龄50~54岁,且合并其他一个肺癌高危因素的患者进行筛查,包括职业暴露史或肺部疾病史等。NELSON研究中,筛查人群包括年龄50~74岁人群,吸烟超过10支每天持续时间30年或以上;或吸烟超过15支每天持续时间25年或以上;或目前吸烟者或戒烟不超过10年。NELSON研究中纳入了年龄小雨55岁人群,且吸烟史短于NLST研究。

筛查是降低肺癌高危人群疾病负荷的重要手段,有效筛查手段的衡量标准为病死率降低。本研究旨在探索不符合USPSTF筛查标准的潜在高危人群与符合筛查标准人群相比,是否具有相似的OS。

方法

这是一项前瞻性的观察性队列研究,从梅奥诊所和美国一个社区医院招募了病理确诊为原发性肺癌,年龄50~80岁,吸烟史为30年或以上,当下吸烟者或戒烟不超过30年。所有年龄55~80岁的人群定义为符合USPSTF标准(USPSTF组)或长期戒烟者。所有戒烟不超过15年的患者分为两组,符合USPSTF组(年龄55~80岁)和年轻组(年龄50~54岁)。

结果

1997年1月1日至2017年12月31日,共纳入8739例肺癌患者并进行随访,中位随访时间为6.5年,其中7846例(90%)为白人。社区队列共941例患者,医院队列共7798例患者。年龄55~80岁之间,戒烟不超过30年的8021例患者,根据是否符合USPSTF标准进行划分,不符合USPSTF筛查标准的长期吸烟者年龄显著更大,男性更多见,吸烟包年数更少,腺癌患者比例更高。

总体人群的中位生存期为16.9个月,长期戒烟者、年轻患者组和符合USPSTF标准组患者的5年OS率分别为27%、22%和23%。

在单因素Cox模型中,已知的预后因素包括年龄、性别、种族、吸烟史、吸烟包年、肿瘤组织学类型、分期和治疗形式。在多因素分析中,医院队列分析显示,长期戒烟者和和符合USPSTF标准的患者,5年OS率无显著差异(HR 1.02;95%CI:0.94-1.10,P=0.72),见下图1A。在社区队列中,长期戒烟者和和符合USPSTF标准的患者,5年OS率仍然相似(HR 0.97;95%CI 0.75-1.26,P=0.82),见下图1B。


图1. 多因素Cox比例风险模型对比满足USPSTF筛查和长期戒烟者的OS

年龄50~80岁,戒烟不超过15年的7335例患者中,根据USPSTF标准,医院队列和社区队列分别有5869例和758例患者满足USPSFT筛查标准。在两个个队列中,患者主要为男性和白人,符合USPSTF标准的患者和年轻患者组的诊断年龄存在显著差异。大多数患者为当下吸烟者。大多数患者诊断时分期为III~IV期,最常见的组织学类型为腺癌。相比于USPSTF组,年轻患者组多为当下吸烟者,大多数患者为女性、III/IV期腺癌。

在医院队列中,年轻患者组和符合USPSTF标准组患者的中位OS分别为17.4 vs 17.2个月,5年OS率分别为22% vs 23%,无显著差异(P=0.78,见图2A)。在社区队列中,年轻患者组和符合USPSTF标准组患者的中位OS分别为14.7 vs 12.8个月,5年OS率分别为16% vs 23%,无显著差异(P=0.57,见图2B)。在单因素Cox分析中,性别、吸烟状态、吸烟包年、戒烟时间、肿瘤组织学类型、分期和治疗形式都是有意义的变量,纳入多因素分析。结果显示,在医院队列和USPSTF组中,年轻患者组和符合USPSTF组患者的5年生存率无显著差异(HR 1.16;95%CI:0.98-1.38;P=0.08),见图3A。在社区队列中,年轻患者组和USPSTF组的5年生存率也无显著差异(HR 1.16;95%CI:0.74-1.82;P=0.52),见图3B。



图2. 年轻患者组和USPSTF组患者OS对比



图3. 多因素Cox比例风险模型对比满足USPSTF筛查和年轻患者组的OS

结论和讨论

这一前瞻性、观察性队列研究结果提示,对于不满足USPSTF标准(长期戒烟者和年轻患者)的肺癌患者和满足USPSTF标准的患者对比,5年OS率相似。同时,研究也提示长期戒烟者和年轻患者同样面临着较高的肺癌风险。对年轻患者进行筛查可能可以帮助其戒烟。扩大USPSTF标准,纳入长期戒烟者和年轻患者,可能有助于其早期发现肺癌。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1865670, encodeId=0ed718656e012, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Mar 24 06:15:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830137, encodeId=c8ae183013ea3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Mar 09 06:15:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990691, encodeId=176919906917d, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Mar 18 00:15:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256716, encodeId=0b1f1256e169a, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Jul 02 14:15:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537030, encodeId=6b92153e03015, content=<a href='/topic/show?id=7b6e18196cf' target=_blank style='color:#2F92EE;'>#USPSTF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18196, encryptionId=7b6e18196cf, topicName=USPSTF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=315112772198, createdName=lingqf, createdTime=Tue Jul 02 14:15:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368764, encodeId=427a368e649d, content=mark, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=526e2567988, createdName=小微940490, createdTime=Mon Jul 01 16:31:08 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368716, encodeId=d656368e164a, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Mon Jul 01 06:49:35 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037870, encodeId=32c4103e87083, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon Jul 01 02:15:00 CST 2019, time=2019-07-01, status=1, ipAttribution=)]
    2020-03-24 minlingfeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1865670, encodeId=0ed718656e012, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Mar 24 06:15:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830137, encodeId=c8ae183013ea3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Mar 09 06:15:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990691, encodeId=176919906917d, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Mar 18 00:15:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256716, encodeId=0b1f1256e169a, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Jul 02 14:15:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537030, encodeId=6b92153e03015, content=<a href='/topic/show?id=7b6e18196cf' target=_blank style='color:#2F92EE;'>#USPSTF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18196, encryptionId=7b6e18196cf, topicName=USPSTF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=315112772198, createdName=lingqf, createdTime=Tue Jul 02 14:15:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368764, encodeId=427a368e649d, content=mark, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=526e2567988, createdName=小微940490, createdTime=Mon Jul 01 16:31:08 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368716, encodeId=d656368e164a, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Mon Jul 01 06:49:35 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037870, encodeId=32c4103e87083, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon Jul 01 02:15:00 CST 2019, time=2019-07-01, status=1, ipAttribution=)]
    2020-03-09 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1865670, encodeId=0ed718656e012, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Mar 24 06:15:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830137, encodeId=c8ae183013ea3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Mar 09 06:15:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990691, encodeId=176919906917d, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Mar 18 00:15:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256716, encodeId=0b1f1256e169a, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Jul 02 14:15:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537030, encodeId=6b92153e03015, content=<a href='/topic/show?id=7b6e18196cf' target=_blank style='color:#2F92EE;'>#USPSTF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18196, encryptionId=7b6e18196cf, topicName=USPSTF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=315112772198, createdName=lingqf, createdTime=Tue Jul 02 14:15:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368764, encodeId=427a368e649d, content=mark, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=526e2567988, createdName=小微940490, createdTime=Mon Jul 01 16:31:08 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368716, encodeId=d656368e164a, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Mon Jul 01 06:49:35 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037870, encodeId=32c4103e87083, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon Jul 01 02:15:00 CST 2019, time=2019-07-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1865670, encodeId=0ed718656e012, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Mar 24 06:15:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830137, encodeId=c8ae183013ea3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Mar 09 06:15:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990691, encodeId=176919906917d, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Mar 18 00:15:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256716, encodeId=0b1f1256e169a, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Jul 02 14:15:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537030, encodeId=6b92153e03015, content=<a href='/topic/show?id=7b6e18196cf' target=_blank style='color:#2F92EE;'>#USPSTF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18196, encryptionId=7b6e18196cf, topicName=USPSTF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=315112772198, createdName=lingqf, createdTime=Tue Jul 02 14:15:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368764, encodeId=427a368e649d, content=mark, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=526e2567988, createdName=小微940490, createdTime=Mon Jul 01 16:31:08 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368716, encodeId=d656368e164a, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Mon Jul 01 06:49:35 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037870, encodeId=32c4103e87083, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon Jul 01 02:15:00 CST 2019, time=2019-07-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1865670, encodeId=0ed718656e012, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Mar 24 06:15:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830137, encodeId=c8ae183013ea3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Mar 09 06:15:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990691, encodeId=176919906917d, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Mar 18 00:15:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256716, encodeId=0b1f1256e169a, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Jul 02 14:15:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537030, encodeId=6b92153e03015, content=<a href='/topic/show?id=7b6e18196cf' target=_blank style='color:#2F92EE;'>#USPSTF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18196, encryptionId=7b6e18196cf, topicName=USPSTF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=315112772198, createdName=lingqf, createdTime=Tue Jul 02 14:15:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368764, encodeId=427a368e649d, content=mark, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=526e2567988, createdName=小微940490, createdTime=Mon Jul 01 16:31:08 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368716, encodeId=d656368e164a, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Mon Jul 01 06:49:35 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037870, encodeId=32c4103e87083, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon Jul 01 02:15:00 CST 2019, time=2019-07-01, status=1, ipAttribution=)]
    2019-07-02 lingqf
  6. [GetPortalCommentsPageByObjectIdResponse(id=1865670, encodeId=0ed718656e012, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Mar 24 06:15:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830137, encodeId=c8ae183013ea3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Mar 09 06:15:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990691, encodeId=176919906917d, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Mar 18 00:15:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256716, encodeId=0b1f1256e169a, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Jul 02 14:15:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537030, encodeId=6b92153e03015, content=<a href='/topic/show?id=7b6e18196cf' target=_blank style='color:#2F92EE;'>#USPSTF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18196, encryptionId=7b6e18196cf, topicName=USPSTF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=315112772198, createdName=lingqf, createdTime=Tue Jul 02 14:15:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368764, encodeId=427a368e649d, content=mark, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=526e2567988, createdName=小微940490, createdTime=Mon Jul 01 16:31:08 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368716, encodeId=d656368e164a, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Mon Jul 01 06:49:35 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037870, encodeId=32c4103e87083, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon Jul 01 02:15:00 CST 2019, time=2019-07-01, status=1, ipAttribution=)]
    2019-07-01 小微940490

    mark

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1865670, encodeId=0ed718656e012, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Mar 24 06:15:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830137, encodeId=c8ae183013ea3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Mar 09 06:15:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990691, encodeId=176919906917d, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Mar 18 00:15:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256716, encodeId=0b1f1256e169a, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Jul 02 14:15:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537030, encodeId=6b92153e03015, content=<a href='/topic/show?id=7b6e18196cf' target=_blank style='color:#2F92EE;'>#USPSTF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18196, encryptionId=7b6e18196cf, topicName=USPSTF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=315112772198, createdName=lingqf, createdTime=Tue Jul 02 14:15:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368764, encodeId=427a368e649d, content=mark, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=526e2567988, createdName=小微940490, createdTime=Mon Jul 01 16:31:08 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368716, encodeId=d656368e164a, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Mon Jul 01 06:49:35 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037870, encodeId=32c4103e87083, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon Jul 01 02:15:00 CST 2019, time=2019-07-01, status=1, ipAttribution=)]
    2019-07-01 深海的鱼

    学习学习学习

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1865670, encodeId=0ed718656e012, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Mar 24 06:15:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830137, encodeId=c8ae183013ea3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Mar 09 06:15:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990691, encodeId=176919906917d, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Mar 18 00:15:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256716, encodeId=0b1f1256e169a, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Jul 02 14:15:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537030, encodeId=6b92153e03015, content=<a href='/topic/show?id=7b6e18196cf' target=_blank style='color:#2F92EE;'>#USPSTF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18196, encryptionId=7b6e18196cf, topicName=USPSTF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=315112772198, createdName=lingqf, createdTime=Tue Jul 02 14:15:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368764, encodeId=427a368e649d, content=mark, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=526e2567988, createdName=小微940490, createdTime=Mon Jul 01 16:31:08 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368716, encodeId=d656368e164a, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Mon Jul 01 06:49:35 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037870, encodeId=32c4103e87083, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Mon Jul 01 02:15:00 CST 2019, time=2019-07-01, status=1, ipAttribution=)]
    2019-07-01 anti-cancer

    谢谢梅斯分享这么多精彩信息

    0

相关资讯

Nature:中科院研究,有望抑制肺癌转移!

在由中科院上海生化细胞所杨巍维博士与中国科学院大连化学物理研究所李国辉博士研究组合作发表于《Nature》的一篇研究中,研究者们进一步探索了癌症转移的机制,并为预防肿瘤转移提供一些新的思路。

CA-CANCER J CLIN: 多种癌症的筛查指南

乳腺癌:40-54岁,1次/年,钼靶X线检查;55岁及以上,预期寿命长于10年,每年筛查2次。宫颈癌:21-29岁,1次/3年,常规的或巴式细胞法;30-65岁,1次/3年,巴式细胞法,或1次/5年,HPV检测+巴式细胞法;65岁以上,若在过去10年内连续3次巴式细胞法检测阴性或连续2次巴式细胞法+HPV检测阴性,则可终止宫颈癌筛查。PS. 宫颈癌疫苗注射与否,不影响筛查方案。子宫内膜癌:更年期的

开启局部晚期肺癌治疗“新模式”——听吴一龙教授解读CTONG1103研究发现

由广东省人民医院吴一龙教授和钟文昭教授牵头进行的全国多中心随机对照II期临床研究EMERGING(CTONG1103),旨在对比厄洛替尼和传统含铂双药作为IIIA N2期非小细胞肺癌(NSCLC)新辅助治疗的疗效及安全性。研究结果首次在2018年ESMO大会发布,2019年6月13日在JCO杂志正式发布。

陆舜教授:促进亚太地区肺癌诊疗水平的提高,中国专家任重而道远

浴兰时节,菖蒲酒美,契阔谈宴恰逢时。践行“一带一路”倡议,借助区域合作平台,积极拓展中国与亚太国家和地区的科学交流与合作,不遗余力推动“中国健康创新模式”,2019年6月13—14日,阿斯利康泛亚肺癌高峰论坛(Pan-Asia Lung Cancer Summit)隆重召开。会议邀请到韩国延世大学医学院的Byoung Chul Cho教授、美国Levine癌症研究所的Edward S.Kim教授,

Nature:杨巍维教授发现尿酸代谢关键酶能抑制肺癌转移

6月26日,中国科学院生物化学与细胞生物学研究所杨巍维(YANG Weiwei)博士与中国科学院大连化学物理研究所李国辉博士领导的研究小组在《Nature》杂志上发表了一项研究报告:“尿苷二磷酸葡萄糖(UDP-glucose)不仅是尿酸代谢中的代谢中间产物,而且它还有一个新功能——加速SNAI1 mRNA衰变阻止肺癌转移。”这一发现很重要,因为肺癌是中国乃至世界最主要的癌症杀手,估计95%的癌症死

抗肿瘤药物处方审核专家共识—肺癌

为了进一步规范肿瘤的药物治疗,促进临床合理用药,改善肺癌患者的预后,由国家癌症中心、国家肿瘤质控中心药事质控专家委员会牵头,中国抗癌协会肿瘤临床药学专业委员会、中国药师协会肿瘤药师分会共同组织全国药学专家,根据《医疗机构处方审核规范》及抗肿瘤药物管理相关规定,结合目前国内肿瘤专科药师临床处方审核的实践经验,制定了《肺癌抗肿瘤药物处方审核专家共识》。 本共识首次提出运用“六步法”进行抗肿瘤药物处方审